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Abstract 
White coat syndrome or hypertension is a condition where patients in a clinic setting exhibit 
above-the-normal-range blood pressure level, but a normal blood pressure range when in other 
settings such as home. White coat syndrome often progresses to sustained hypertension, alters 
left ventricular diastolic function and the elastic properties of the aorta. The variability of blood 
pressure that is the fluctuations of blood pressure with time increases stiffness of the major 
arteries in the body. These changes may eventually lead to target organ damage or stroke. It is 
believed that these changes are the cause for end target organ damage that occurs. There are 
different opinions when it comes to treating white coat syndrome, the general consensus by the 
researchers (which will be discussed in subsequent paragraphs) is to perform further studies with 
larger population sizes over a longer time frame of study. This is relevant since the percent of 
adults ages 20 and over with hypertension is 33.5% (CDC, 2017). This number is growing in our 
society and any and all information is important in the diagnosis and treatment of this condition 
to prevent the detrimental effects of end target organ damage, high costs of treatment, lost 
productivity of employees in the workforce and mortality. 
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Background 
My clinical topic focused on researching into white coat syndrome comparing to essential 
or true hypertension and noting if any possible cardiac differences exist between the two. A 67-
year old white female who came into the office for a three-week follow-up after prescribed 
lisinopril 20mg taken once daily. The patient developed an angiotensive converting enzyme 
inhibitor (ACEI)-induced cough, severe enough to consider alternative therapies and different 
medications, not only for the unpleasant side effects from lisinopril but also to better manage her 
blood pressure (BP). Since the patient continued to have elevated blood pressure additional 
investigation and treatment was warranted. Further querying of the patient’s history revealed that 
her BP readings at home were also high in the 160/90 mmHg range. 
White coat hypertension (WCH), or as it is commonly known as white coat syndrome 
(WCS), is a phenomenon when patients exhibit above-the-normal-range blood pressure level, in 
a clinical setting and not in other settings. There is some belief that this phenomenon maybe 
related to anxiety experienced by patients during a clinic visit. There is evidence to show that 
increases in BP are the leading cause of coronary artery disease (CAD), stroke, arrhythmia, and 
death (Ermis et al., 2016). White coat syndrome prevalence increases with age, progresses to true 
hypertension, and causes end target organ damage (Puchales et al., 2010). 
Although numerous studies have been conducted on WCS in determining the prognostic 
significance, it remains unclear. There is some controversy when it comes to diagnosis and 
treatments of WCS. The instrument BP cuff used to measure the BP, activities before the 
appointments, and anxiety could all cause a false high BP reading. The purpose of this report is 
to learn more about WCS, whether there are different cardiovascular outcomes between this and 
true hypertension.  
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Case Report 
A 67-year-old Caucasian female presented to the primary care office for follow-up on 
hypertension (HTN). She denied any significant past medical history other than “the occasional 
seasonal sinus issues” for which she used over the counter antihistamine Claritin, which relieved 
the sinus symptoms. Also, she was diagnosed with hypertension three-weeks ago, and was 
prescribed lisinopril 20mg daily at that appointment. Since starting the medication she voiced 
noticing a dry, irritating cough that was worse at night and even woke her from sleep. She 
monitors her blood pressure every morning with readings usually in the 160/80mmHg range and 
a heart rate between 60 to 70 beats per minute. She voiced health maintenance lab work was 
completed about six months prior to this visit. The results of the lab work showed her basic 
metabolic panel (BMP) to be within normal range, but the results of the lipid panel revealed 
elevated low density lipoprotein (LDL); She was advised by the health care provider to engage in 
exercise program as well as weight-loss to decrease the risk of cardiovascular diseases. 
She denied dizziness, palpitations, or chest pain. She was one pack per day smoker for 
fifteen years and quit for ten years. She admitted alcohol consumption weekly. Health 
maintenance practice includes annual eye exams, dental visits, and regular exercise of water 
aerobic. Her familial history includes coronary artery disease in her father, mother, and oldest 
brother who had multiple coronary bypass surgeries. 
The physical exam reveals a well nourished, non-toxic appearing female who is age 
appropriate and answered questions appropriately. Her heart rate was regular, no jugular venous 
distention (JVD) or murmur appreciated, and lungs were clear bilaterally on auscultation. Her 
hands and feet showed no edema. She had normal bowel sounds auscultated in all four 
quadrants, abdomen was soft and non-tender, and had no CVA tenderness appreciated, and 
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genitourinary exam was deferred by patient. Blood pressure reading in office was 160/80mmHg 
with a pulse of 80. 
Diagnosis of uncontrolled Hypertension, Angiotensive Converting Enzyme Inhibitor 
(ACEI) induced cough, and Borderline low density lipoproteins (LDL) were made. The lipid 
panel was repeated to monitor LDL as well a comprehensive metabolic panel (CMP) in the 
office which showed only elevated LDL level. 
The treatment plan for the uncontrolled hypertension and ACEI-induced cough include:  
• Discontinuing Lisinopril due to ACEI-induced cough and starting on hydrochlorothiazide 
(HCTZ) 25mg to be taken orally daily starting following morning.  
• Monitoring blood pressure randomly together with heart rate and bring results with to 
next appointment in one month.  
• Encouraging to continue with water aerobics three times/week.  
• Advised on risk factors of cardiovascular events and to cut down salt intake.  
• Informed that we plan to do another BMP on next appointment to monitor kidney 
function and for any electrolyte imbalance 
Pertaining to the borderline LDL treatment she will be started on fish oil 1000mg twice a day. 
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Literature Review 
The fore mentioned case report about hypertension raised the question about white coat 
hypertension or white coat syndrome does it exist? It was postulated that it may not be real. Also, 
could there be any cardiovascular outcomes between WCS and “normal”/ true hypertension. 
Researching current literature revealed some interesting information, which will be discussed in 
the subsequent paragraphs. 
The prevalence of WCS increases with age and about 45% of patients over the age of 65 
have been diagnosed with this condition. The authors defined WCS as systolic blood pressure of 
greater than 140 mmHg and a diastolic blood pressure greater than 90 mmHg without any 
antihypertensive treatment in the office setting (Puchales et al., 2010). Left ventricular 
hypertrophy was also found in WCS, the prevalence of left ventricular hypertrophy (LVH) in 
WCS was found to be about 50%. Also, the more abnormalities that are present in the left 
ventricle, the higher the chances of increased mortality (Puchales et al., 2010). This suggests that 
WCS over a prolonged time may be associated with cardiac damage, and may have prognostic 
implications for morbidity or mortality. Huang et al. (2017) researched whether or not WCS is a 
risk factor for cardiovascular disease and mortality. WCS without antihypertensive treatment was 
associated with long-term risk of cardiovascular disease (CVD) and total mortality in patients, 
and suggested that more monitoring or close follow-up should be performed in these WCS 
patients (Huang et al., 2017). In elderly people, WCS is linked with cardiac structural 
abnormalities comparable to what is seen in people with sustained hypertension (Puchales et al., 
2010). Ermis et al. (2016) also found that WCS was linked with a higher risk of developing 
persistent hypertension, and it also had an effect on target organ damage. 
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Ermis et al. (2016) did a study looking at left atrial volume and function in patients with 
WCS using real-time 3-D echocardiography. The authors also looked at ambulatory BP 
monitoring in WCS individuals. The results showed there were no significant differences 
between the control individuals and the WCS individuals for ambulatory BP monitoring. Krakoff 
(2015) discussed using ambulatory or out of office BP readings to help diagnose and treat WCS 
patients. Krakoff felt this was important to have accurate home BP readings as these will help 
decrease unnecessary treatment of WCS patients. Krakoff found that in some prospective studies 
WCS has a slightly higher risk for future target organ damage than sustained hypertension 
(Krakoff, 2015). Research has been done evaluating the most appropriate medical treatment for 
WCS but it has yet to be determined if these treatment are effective in preventing cardiovascular 
disease in this population (Krakoff, 2015). Krakoff recommended using ambulatory or out of 
office BP readings to detect WCS as it can often reduce the many burdens associated with drug 
treatment for these patients. 
White coat syndrome often progresses to sustained hypertension, and it can alter left 
ventricular (LV) diastolic function and the elastic properties of the aorta. The latter two have 
been identified as markers of target organ damage in hypertension (Ermis et al., 2016). The 
authors discuss another study that showed that 42% of 1412 patients who had WCS had 
developed sustained hypertension during the ten year follow-up. Any changes in the left atrial 
volumes (LAV) can affect the expansion index and ultimately help predict cardiac arrhythmia in 
these patients. The authors concluded that due to the small sample size of the participants, there 
is the need for a large scale prospective study with a longer term follow-up (Ermis et al., 2016). 
The authors concluded that the impaired left atrium may lead to atrial arrhythmia, but further 
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studies are required to determine the prognostic power of atrial measurements for cardiovascular 
events in WCS patients. 
Shehab and Abdulle (2011) in their study focused on cognitive and autonomic 
dysfunction (specifically heart rate variability) in WCS, the authors also found WCS did 
contribute a risk for cardiovascular disease. The authors explored the hemodynamic differences 
and presence of any functional changes. The results found that patients with WCS performed less 
in the memory test, and echocardiogram revealed no significant differences in left ventricle mass 
indices and diastolic function. The authors concluded that WCS may not be a benign condition as 
previously thought and may contribute to an overall risk for left ventricle damage and 
cardiovascular disease. A recommendation is to do a longitudinal study of WCH patients to 
clarify the progressive nature of this condition (Shehab & Abdulle, 2011). There is existing 
evidence that indicates that WCS may develop into persistent or true hypertension over time.  
Briasoulis, Androulakis, Palla, Papageorgiou, and Tousoulis (2016), performed a 
systematic review to determine the effects of WCS on cardiovascular events, stroke, and death. 
They found that patients with WCS had a slight, higher rate of cardiovascular disease, morbidity 
and mortality compared to normotensive patients. Also, WCS may develop into true 
hypertension which carries slightly, higher, cardiovascular risk especially if other risk factors are 
present. Briasoulis et al. (2016) recommend further studies that will focus on participants with 
WCS who are at higher risk of progressing to sustained or true hypertension since these patients 
would benefit from treatment to decrease cardiovascular morbidity and mortality. Based on the 
results of their study WCS is real, and there was no mention of cardiac difference between this 
and sustained or true hypertension (Briasoulis et al., 2016). 
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Another study performed by Cacciolati, Hanon, Dufouil, Alpérovitch, and Tzourio (2013) 
looked at a one-year follow-up in elderly patients with untreated WCS and the risk of developing 
sustained hypertension. The elderly with high office BP readings had a three-fold increased risk 
of developing sustained or normal hypertension a year later. The authors went on to say that the 
elderly are at higher risk for developing hypertension-related diseases such as strokes, heart and 
renal failure; thus it is important to understand the risk of sustained hypertension in the elderly 
(Cacciolati et al., 2013). The study mentioned conflicting thoughts as to whether WCS increases 
a patient’s risk of target organ damage.  
Franklin, Thijs, Hansen, O'Brien, and Staessen (2013) looked at cardiovascular risk 
associated with WCH. Patients with untreated WCH failed to show a progressive increase in 
cardiovascular risk over time and did not progress to sustained hypertension. This could also be 
due to the fact that patients were selected inappropriately with high-normal blood pressure and 
not WCS, and this could also be the reason for the failure to progress to sustained hypertension. 
There is the belief that it may be beneficial to treat high-risk patients with white-coat 
hypertension, but this is untested by randomized controlled trials. A small study was performed 
treating WCS in elderly patients but there was no evidence of beneficial effect of active 
treatment on ECG voltages or stroke incidence. Patients with high cardiovascular risk and 
showing evidence of hypertensive target organ damage should not only institute lifestyle changes 
but to make a treatment decision based on documented elevated 24-hour ambulatory or home BP 
readings (Franklin et al., 2013). 
Muntner, Booth III, Shimbo, and Schwartz (2017) performed a meta-analysis study 
looking at data from previous studies to determine if WCS led to higher risk of cardiovascular 
outcomes; and diagnosing WCS accurately to prevent unwarranted use of antihypertensive 
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medication. There is a tremendous need to identify the cardiovascular risk in the WCS 
population due to the high prevalence of WCS. The authors after reviewing the meta-analysis 
suggested screening for WCS with ambulatory or home BP monitoring thus avoiding the 
unwarranted initiation of antihypertensive medication. 
Kaplan and Townsend (2015) had suggestions for minimizing WCS such as decreasing 
anxiety, which is one of the contributors of WCS. This could include having the nurse or 
technician take the BP reading rather than the clinician, or using an automated oscillometric 
blood pressure monitor. Also, it takes about three to six visits for a new patient to a doctor’s 
office to reach a stable BP value; therefore if the patient has a mild to moderate elevation in BP, 
it would be reasonable to delay diagnosis of WCS until about the sixth visit. Exceptions to this 
include the patient’s blood pressure that remains elevated after three to six visits or there is 
evidence of ongoing end-organ damage. The cardiovascular risk connected to WCS may be 
slightly higher than in a normotensive patient as well as a significantly higher rate of mortality 
during a sixteen-year follow-up. WCS patients are at a high risk of developing sustained 
hypertension. This seems to be the general consensus that is the progression to sustained or 
normal hypertension (Kaplan & Townsend, 2015). 
In conclusion whether WCS is an innocent phenomenon is controversial. Ermis et al., 
Puchales et al., Huang et al., Briasoulis et al., and Krakoff concluded from their studies WCS 
increased the risk of cardiovascular disease. Also, there was slightly higher risk of causing target 
organ damage and if not treated could lead to mortality. Shehab and Abdulle also found WCS 
may contribute an overall risk for cardiovascular disease. When it comes to treating or not to 
treat there are divided opinions as well. There is not enough data to support the effectiveness of 
drug treatment in reducing the potential for cardiovascular disease risk. Krakoff and Briasloulis 
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et al., recommended using ambulatory or out of office BP readings to detect WCS as it can often 
reduce the many burdens associated with drug treatment for these patients. There are no 
cardiovascular differences between WCS patients and patients with sustained or true 
hypertension as confirmed by the studies in previous paragraphs, but further studies with larger 
population size and a longer time frame of study is needed. 
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Learning Points 
➢ White coat hypertension is a known medical phenomenon. Research while 
somewhat limited has not been able to identify cardiac differences between those 
diagnosed with WCS and essential hypertension.  
➢ White coat syndrome is a well-documented medical condition affecting an 
estimated 33.5% of people in America. Some research has evidence to support 
that it does eventually lead to target organ damage, increases risk of stroke, and 
cardiovascular disease. Left ventricular hypertrophy may be an early sign of end-
organ damage, which is otherwise undetectable, and the best way to do so is to 
perform an echocardiogram. 
➢ The role of white-coat hypertension (WCH) in development of cardiovascular 
disease (CVD) risk remains poorly understood. There is evidence to show 
changes in the left ventricle, left ventricle hypertrophy, and stiffness in the artery 
over time increases the risk for CVD. The research recommends a larger 
population sample to be used and also long-term follow-up. 
➢ There may be some benefit to treat high-risk patients with white-coat 
hypertension; this is however untested by randomized controlled trials.  
➢ In a small study performed elderly patients with WCS were treated but there was 
no evidence of beneficial effect of active treatment on ECG voltages or stroke 
incidence.  
➢ Patients with high cardiovascular risk and showing evidence of hypertensive 
target organ damage should institute lifestyle changes. Treatment decision should 
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be based on documented elevated 24-hour ambulatory or home BP readings and 
not in office readings.  
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